REspiratory Syncytial virus Consortium in EUrope (RESCEU) study: Defining the burden of disease of Respiratory Syncytial Virus in older adults in Europe.

Completed

• Conditions: RSV-infection; RS-virus infection; 10047438; 10024970

• Registration Number: NL-OMON45431
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Trial is onging in other countries

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2019-07-16
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 356

Inclusion Criteria

- Male and female adults *60 years of age
- Willing and able to give written informed consent
- Willing and able to adhere to protocol-specified procedures

Exclusion Criteria

- Current alcohol or drug abuse or history of unsuccessfully treated alcohol or drug abuse within the past year
- Unable to perform the study procedures
- Dementia
- Life expectancy less than 1 year
- Any known or suspected immunosuppressive condition, acquired or congenital, as determined by history and/or physical examination (a more detailed description/list can be found in appendix 3 of the study protocol).
- Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to study participation. The use of topical, inhaled, and nasal glucocorticoids will be permitted (a more detailed description/list can be found in appendix 3 of the study protocol).
- Previous participation in this study or in a RSV interventional trial (vaccine, antivirals)
- Planned leave/holiday during the winter season of more than 1 month in total.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary Objective:<br /><br>* To estimate the incidence of RSV infection-associated ARTI, RSV MA-ARTI and<br /><br>RSV hospitalization in older adults.</p><br>